Investigation of Flare and Remission in Subjects With Atopic Dermatitis

LEO Pharma

Status and phase

Withdrawn

Phase 4

Conditions

Atopic Dermatitis

Treatments

Drug: Cyclosporine A

Study type

Interventional

Funder types

Industry

Identifiers

NCT03710044

EXP-1392

2018-000229-30 (EudraCT Number)

Details and patient eligibility

About

The trial is an exploratory, single-centre, uncontrolled, open-label, interventional trial of up to 19 weeks' duration to investigate flare and remission in subjects with moderate-to-severe atopic dermatitis (AD) treated with cyclosporine A (CsA).

Full description

40 subjects with moderate-to-severe AD will be treated with a 3-week course of high-dose CsA, which is a standard-of-care treatment regimen. After 3 weeks, all responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).

In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria:

Diagnosis and history of chronic, moderate-to-severe AD (by the Eichenfield revised criteria of Hanifin and Rajka) for at least 3 years before the screening visit.
Subjects who have an AD flare at the start of the trial (EASI score ≥10 at screening and ≥16 at the baseline visit).

Main Exclusion Criteria:

Treatment with allergen immunotherapy within 6 months before the baseline visit.
Treatment with leukotriene inhibitors, systemic glucocorticoids, or other systemic treatment for AD (including immunosuppressive treatment, ultraviolet therapy, and biologics) within 4 weeks before the baseline visit.
Treatment with topical corticosteroids or topical calcineurin inhibitors within 1 week before the baseline visit.
Chronic or acute infection requiring treatment with oral or intravenous antibiotics, anti-virals, anti-parasitics, anti-protozoals, or anti-fungals within 4 weeks before the screening visit or superficial skin infections within 1 week before the screening visit.
History of malignancy within 5 years before the baseline visit, with the following exceptions: subjects with a history of completely treated carcinoma in situ of cervix, and non-metastatic squamous or basal cell carcinoma of the skin are allowed.
Hypertension (>150/95 mmHg) at the screening visit.
Planned surgical procedure during the length of the subject's participation in this trial.
Use of a tanning booth/parlour within 4 weeks before the screening visit.
Pregnant, breastfeeding, or lactating women.
Laboratory abnormalities at the screening visit.